CZ20032564A3 - Značené antagonisty receptoru makrofágového lapače pro zobrazování atherosklerosy a citlivých plaků - Google Patents

Značené antagonisty receptoru makrofágového lapače pro zobrazování atherosklerosy a citlivých plaků Download PDF

Info

Publication number
CZ20032564A3
CZ20032564A3 CZ20032564A CZ20032564A CZ20032564A3 CZ 20032564 A3 CZ20032564 A3 CZ 20032564A3 CZ 20032564 A CZ20032564 A CZ 20032564A CZ 20032564 A CZ20032564 A CZ 20032564A CZ 20032564 A3 CZ20032564 A3 CZ 20032564A3
Authority
CZ
Czechia
Prior art keywords
substituted
přij
independently selected
compound
direct bond
Prior art date
Application number
CZ20032564A
Other languages
Czech (cs)
English (en)
Inventor
D. Scott Edwards
Shuang Kiu
Original Assignee
Bristol-Myers Squibb Pharma Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Pharma Company filed Critical Bristol-Myers Squibb Pharma Company
Publication of CZ20032564A3 publication Critical patent/CZ20032564A3/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CZ20032564A 2001-02-23 2002-02-22 Značené antagonisty receptoru makrofágového lapače pro zobrazování atherosklerosy a citlivých plaků CZ20032564A3 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27095401P 2001-02-23 2001-02-23

Publications (1)

Publication Number Publication Date
CZ20032564A3 true CZ20032564A3 (cs) 2004-09-15

Family

ID=23033552

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20032564A CZ20032564A3 (cs) 2001-02-23 2002-02-22 Značené antagonisty receptoru makrofágového lapače pro zobrazování atherosklerosy a citlivých plaků

Country Status (12)

Country Link
US (2) US6869590B2 (enExample)
EP (1) EP1377321A4 (enExample)
JP (1) JP2004530654A (enExample)
CN (1) CN1622832A (enExample)
AU (1) AU2002254000A1 (enExample)
BR (1) BR0207521A (enExample)
CA (1) CA2438174A1 (enExample)
CZ (1) CZ20032564A3 (enExample)
HU (1) HUP0400027A3 (enExample)
IL (1) IL157444A0 (enExample)
MX (1) MXPA03007534A (enExample)
WO (1) WO2002067761A2 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03010035A (es) * 2001-05-02 2004-06-30 Purdue Research Foundation Tratamiento y diagnostico de enfermedades mediadas por macrofagos.
CA2449828A1 (en) * 2001-06-04 2003-01-16 The General Hospital Corporation Detection and therapy of vulnerable plaque with photodynamic compounds
CA2461836A1 (en) * 2001-10-16 2003-04-24 Epix Medical, Inc. Detection and treatment of intravascular lesions
US8043603B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US8043602B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
AU2002337926B8 (en) * 2002-11-05 2008-02-28 Ion Beam Applications S.A. Stabilization of radiopharmaceuticals labeled with 18-F
US7018614B2 (en) * 2002-11-05 2006-03-28 Eastern Isotopes, Inc. Stabilization of radiopharmaceuticals labeled with 18-F
GB0228490D0 (en) * 2002-12-06 2003-01-08 Amersham Plc Novel imaging compounds
US7297154B2 (en) 2003-02-24 2007-11-20 Maxwell Sensors Inc. Optical apparatus for detecting and treating vulnerable plaque
US7153299B1 (en) 2003-02-24 2006-12-26 Maxwell Sensors Inc. Optical apparatus for detecting and treating vulnerable plaque
US7803352B2 (en) * 2003-03-07 2010-09-28 John Steele Fisher Method for continuous visualization of a blood clot or plaque in body lumen
JP4680185B2 (ja) 2003-05-30 2011-05-11 パーデュー・リサーチ・ファウンデーション アテローム性動脈硬化症の診断法
CN1859904A (zh) * 2003-10-03 2006-11-08 默克公司 用于治疗阿尔茨海默氏病的苄醚和苄氨基β－分泌酶抑制剂
EP1602931A1 (en) * 2004-06-03 2005-12-07 Universiteit Leiden SR-A antagonists
US20080206150A1 (en) * 2004-06-25 2008-08-28 The Regents Of The University Of California Nanoparticles for Imaging Atherosclerotic Plaque
US7575738B2 (en) 2004-08-13 2009-08-18 General Electric Company Heat shock protein as a targeting agent for endothelium-specific in vivo transduction
RU2007128036A (ru) * 2004-12-23 2009-01-27 Пердью Рисерч Фаундейшн (Us) Способ получения изображения позитронно-эмиссионной томографией
EP1904183B1 (en) 2005-07-05 2014-10-15 Purdue Research Foundation Pharmaceutical composition for the treatment of osteoarthritis
US7874975B2 (en) * 2005-07-20 2011-01-25 Clear Vascular, Inc. Methods and compositions for treating luminal inflammatory disease
WO2007038346A2 (en) 2005-09-23 2007-04-05 Purdue Research Foundation Multiphoton in vivo flow cytometry method and device
US20070196282A1 (en) * 2006-02-21 2007-08-23 Siemens Medical Solutions Usa, Inc. Medical diagnostic ultrasound with temperature-dependent contrast agents
EP2087337A4 (en) 2006-11-03 2010-09-08 Purdue Research Foundation METHOD AND DEVICE FOR EX-VIVO FLOW CYTOMETRY
EP2109466B1 (en) 2007-02-07 2014-11-12 Purdue Research Foundation Positron emission tomography imaging method
US8961926B2 (en) * 2007-05-25 2015-02-24 Purdue Research Foundation Method of imaging localized infections
RU2474435C2 (ru) * 2007-11-07 2013-02-10 Джи-И Хелткер БВ Стабилизация радиофармацевтических композиций
US9717896B2 (en) 2007-12-18 2017-08-01 Gearbox, Llc Treatment indications informed by a priori implant information
US20090287120A1 (en) 2007-12-18 2009-11-19 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Circulatory monitoring systems and methods
US8636670B2 (en) 2008-05-13 2014-01-28 The Invention Science Fund I, Llc Circulatory monitoring systems and methods
US8361438B2 (en) * 2008-01-08 2013-01-29 Lantheus Medical Imaging, Inc. N-alkoxyamide conjugates as imaging agents
US20100178245A1 (en) * 2009-01-13 2010-07-15 Arnsdorf Morton F Biocompatible Microbubbles to Deliver Radioactive Compounds to Tumors, Atherosclerotic Plaques, Joints and Other Targeted Sites
EP2451776B1 (en) 2009-07-08 2019-09-18 Lantheus Medical Imaging, Inc. N-alkoxyamide conjugates as imaging agents
US20150023873A1 (en) 2011-11-11 2015-01-22 Lantheus Medical Imaging, Inc. Evaluation of presence of and vulnerability to atrial fibrillation and other indications using matrix metalloproteinase-based imaging
DE112016001921B4 (de) 2015-06-09 2025-03-20 Cummins Filtration Ip, Inc. Kurbelgehäuseentlüftungssysteme, die rotierende Tropfenabscheidervorrichtungen verwenden
WO2019034500A1 (en) * 2017-08-15 2019-02-21 Koninklijke Philips N.V. INTRALUMINAL ULTRASONIC DEVICE WITH ADJUSTABLE FREQUENCY
US10933146B2 (en) * 2017-12-12 2021-03-02 Massachusetts Institute Of Technology Cell-permeable imaging sensors and uses thereof
KR102207372B1 (ko) * 2020-03-31 2021-01-27 재단법인 아산사회복지재단 방사성 의약품의 안정화제 및 이를 포함하는 방사성 의약 조성물
CN116473020B (zh) * 2022-11-18 2025-04-25 新乡医学院 一种Macrosialin基因缺失动脉粥样硬化小鼠模型的构建方法及其应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4577042A (en) * 1983-03-17 1986-03-18 California Institute Of Technology Homogeneous coordination compounds as oxidation catalysts
US4678667A (en) 1985-07-02 1987-07-07 501 Regents of the University of California Macrocyclic bifunctional chelating agents
US4752141A (en) 1985-10-25 1988-06-21 Luxtron Corporation Fiberoptic sensing of temperature and/or other physical parameters
EP0247156B1 (en) 1985-11-18 1993-06-23 Access Pharmaceuticals Inc. Polychelating agents for image and spectral enhancement (and spectral shift)
MX174467B (es) 1986-01-23 1994-05-17 Squibb & Sons Inc 1,4,7-triscarboximetil-1,4,7,10-tetraazaciclodo decano substituido en 1 y compuestos analogos
US4885363A (en) 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
GB8603537D0 (en) 1986-02-13 1986-03-19 Parker D Conjugate compound
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
US4923985A (en) 1988-05-25 1990-05-08 The United States Of America As Represented By The Department Of Health & Human Services Process for synthesizing macrocyclic chelates
EP0416033B1 (en) 1988-05-25 1996-03-06 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Macrocyclic chelates and methods of use thereof
US5756065A (en) 1988-06-24 1998-05-26 The Dow Chemical Company Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents
LU87403A1 (fr) 1988-12-06 1990-07-10 Oreal Procede de teinture de fibres keratiniques avec un hydroxyindole,associe a un derive quinonique
DE69024826T2 (de) 1989-02-10 1996-06-27 Celltech Therapeutics Ltd Aza-Macrozyklen und Verfahren zu deren Herstellung
US5914095A (en) 1989-04-07 1999-06-22 Salutar, Inc. Polychelants containg amide bonds
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US4986671A (en) 1989-04-12 1991-01-22 Luxtron Corporation Three-parameter optical fiber sensor and system
US5087440A (en) 1989-07-31 1992-02-11 Salutar, Inc. Heterocyclic derivatives of DTPA used for magnetic resonance imaging
AU7587091A (en) 1990-03-26 1991-10-21 United States of America, as represented by the Secretary, U.S. Department of Commerce, The A fonctionalized complexand
US5275594A (en) 1990-11-09 1994-01-04 C. R. Bard, Inc. Angioplasty system having means for identification of atherosclerotic plaque
EP0565930A1 (en) 1992-03-27 1993-10-20 Nihon Medi-Physics Co., Ltd. Tetraazacyclododecane tetraacetic acid derivatives and the use thereof as diagnostic agents
US5310535A (en) 1992-04-24 1994-05-10 The Dow Chemical Company Carboxamide modified polyamine chelators and radioactive complexes thereof for conjugation to antibodies
US5744120A (en) 1993-03-30 1998-04-28 The Dupont Merick Pharmaceutical Company Ternary radiopharmaceutical complexes
US5428156A (en) 1993-04-02 1995-06-27 Associated Universities, Inc. Synthesis of macrocyclic polyaminocarboxylates and their use for preparing stable radiometal antibody immunoconjugates for therapy, spect and pet imaging
AU2194695A (en) 1994-03-28 1995-10-17 Regents Of The University Of California, The Method for preparing radionuclide-labeled chelating agent-ligand complexes
IT1283218B1 (it) 1996-03-08 1998-04-16 Bracco Spa Polichelanti, loro complessi con ioni metallici, loro preparazione e loro usi
US5879659A (en) 1996-03-13 1999-03-09 Dupont Pharmaceuticals Company Ternary radiopharmaceutical complexes
US5848367A (en) 1996-09-13 1998-12-08 Sony Corporation System and method for sharing a non-volatile memory element as a boot device
US6403054B1 (en) 1997-05-28 2002-06-11 Bristol-Myers Squibb Pharma Company Ternary ligand complexes useful as radiopharmaceuticals
WO1999007382A1 (en) 1997-08-06 1999-02-18 Smithkline Beecham Corporation Macrophage scavenger receptor antagonists for use in the treatment of cardiovascular diseases
CA2328457A1 (en) 1998-06-20 1999-12-29 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
WO2000003704A1 (en) * 1998-07-20 2000-01-27 Smithkline Beecham Corporation Macrophage scavenger receptor antagonists
JP2002521437A (ja) 1998-07-30 2002-07-16 スミスクライン・ビーチャム・コーポレイション マクロファージ・スカベンジャー受容体アンタゴニスト

Also Published As

Publication number Publication date
BR0207521A (pt) 2004-06-01
IL157444A0 (en) 2004-03-28
AU2002254000A1 (en) 2002-09-12
JP2004530654A (ja) 2004-10-07
EP1377321A2 (en) 2004-01-07
US6974567B2 (en) 2005-12-13
US20040057900A1 (en) 2004-03-25
MXPA03007534A (es) 2003-12-04
CA2438174A1 (en) 2002-09-06
US20020127181A1 (en) 2002-09-12
HUP0400027A2 (hu) 2004-04-28
US6869590B2 (en) 2005-03-22
WO2002067761A2 (en) 2002-09-06
EP1377321A4 (en) 2006-01-11
WO2002067761A3 (en) 2003-02-13
HUP0400027A3 (en) 2006-01-30
CN1622832A (zh) 2005-06-01

Similar Documents

Publication Publication Date Title
US6869590B2 (en) Labeled macrophage scavenger receptor antagonists for imaging atherosclerosis and vulnerable plaque
US20250057993A1 (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers
CN109053616B (zh) 前列腺特异性膜抗原(psma)的标记的抑制剂及其用途
Bandari et al. Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN (7-14) NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer
Imberti et al. Enhancing PET signal at target tissue in vivo: dendritic and multimeric tris (hydroxypyridinone) conjugates for molecular imaging of αvβ3 integrin expression with gallium-68
CN108290924A (zh) 肽硫脲衍生物、含有其的放射性同位素标记化合物、和含有该化合物作为活性成分的用于治疗或诊断前列腺癌的药物组合物
JPH07149799A (ja) 新規化合物及びその製造方法並びに診断用薬剤
US9789211B2 (en) Methods and compositions for positron emission tomography myocardial perfusion imaging
Zhao et al. Synthesis and evaluation of 68Ga-and 177Lu-labeled (R)-vs (S)-DOTAGA prostate-specific membrane antigen-targeting derivatives
Li et al. Advances in macrocyclic chelators for positron emission tomography imaging
Shi et al. [68Ga] Ga-HBED-CC-DiAsp: A new renal function imaging agent
CN117120099A (zh) 双模式放射性示踪剂和疗法
EP4338757A1 (en) New pet tracer for imaging of the functional liver reserve
JP4878119B2 (ja) エナンチオマー純粋な（４Ｓ，８Ｓ）−及び（４Ｒ，８Ｒ）−４−ｐ−ニトロベンジル−８−メチル−３，６，９−トリアザ−３Ｎ，６Ｎ，９Ｎ−トリカルボキシメチル−１，１１−ウンデカン二酸及びそれらの誘導体、それらの製造方法並びに医薬品の製造のためのそれらの使用
Lu et al. Design, synthesis, and biological evaluation of a 99m Tc-labeled small-molecule tracer for PD-L1 imaging
Prinsen et al. Synthesis and biological evaluation of 68Ga-bis-DOTA-PA as a potential agent for positron emission tomography imaging of necrosis
WO2001047564A2 (en) Labelled ascorbic acid derivatives
EP4640240A1 (en) Peptide-based radiopharmaceuticals for non-invasive imaging of the functional liver reserve
CN103275188B (zh) 放射性标记t140类多肽化合物及其制备方法和应用
HK40120870A (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers
Müller et al. Folate Receptor-Targeted Radionuclide Imaging Agents
KR20250011145A (ko) 개선된 신장 청소율을 갖는 전립선-특이적 막 항원(psma) 리간드
KR20120027023A (ko) 섬유생성화의 ｐｅｔ 영상화
Harriss Functionalised Microbubbles for Dual-modality Imaging